Applied Biomath, Celsius Therapeutics partner on pharmacology modeling in IBD

By The Science Advisory Board staff writers

December 8, 2021 -- Applied Biomath and Celsius Therapeutics are collaborating on the development of a semimechanistic pharmacokinetic/receptor occupancy model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).

Applied Biomath offers software and services to help de-risk and accelerate drug R&D. The company's approach involves working with clients to develop the appropriate mathematical strategy for each unique project, with common biosimulation strategies deployed, including systems pharmacology, mechanistic modeling, pharmacokinetic/pharmacodynamic modeling, bioinformatics, and clinical pharmacology.

Celsius Therapeutics will use the model developed by Applied Biomath to support human dose projections in IBD.

No terms of the agreement were disclosed.

Applied Biomath highlights presentations at SITC meeting
Applied Biomath is highlighting two poster presentations being offered at the upcoming Society for Immunotherapy of Cancer (SITC) meeting in Washington,...
Athos, Cleveland Clinic to partner on IBD research
Athos Therapeutics and the Cleveland Clinic have agreed to collaborate on inflammatory bowel disease (IBD) research. The agreement will advance the use...
Servier acquires oncology arm of Agios, partners with Celsius
French pharmaceutical company Servier announced that it has entered into an agreement to acquire the oncology business of Agios Pharmaceuticals. In a...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter